Name | Number of supported studies | Average coverage | |
---|---|---|---|
astrocyte | 12 studies | 32% ± 14% | |
microglial cell | 11 studies | 36% ± 16% | |
ciliated cell | 10 studies | 31% ± 14% | |
macrophage | 9 studies | 37% ± 17% | |
glutamatergic neuron | 8 studies | 34% ± 21% | |
GABAergic neuron | 7 studies | 47% ± 25% | |
endothelial cell | 6 studies | 29% ± 10% | |
plasma cell | 5 studies | 33% ± 14% | |
dendritic cell | 5 studies | 25% ± 8% | |
myeloid cell | 5 studies | 30% ± 12% | |
squamous epithelial cell | 4 studies | 33% ± 14% | |
epithelial cell | 4 studies | 38% ± 16% | |
T cell | 4 studies | 23% ± 5% | |
type II pneumocyte | 4 studies | 25% ± 4% | |
B cell | 3 studies | 20% ± 4% | |
CD4-positive, alpha-beta T cell | 3 studies | 20% ± 0% | |
abnormal cell | 3 studies | 22% ± 5% | |
mast cell | 3 studies | 37% ± 19% | |
club cell | 3 studies | 20% ± 4% | |
monocyte | 3 studies | 23% ± 5% | |
natural killer cell | 3 studies | 26% ± 5% | |
type I pneumocyte | 3 studies | 19% ± 1% | |
lymphocyte | 3 studies | 37% ± 11% | |
interneuron | 3 studies | 51% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
thymus | 100% | 4908.01 | 653 / 653 | 99% | 19.77 | 600 / 605 |
kidney | 100% | 3540.38 | 89 / 89 | 98% | 15.68 | 887 / 901 |
lung | 99% | 2009.28 | 574 / 578 | 99% | 18.75 | 1144 / 1155 |
ovary | 99% | 1424.54 | 178 / 180 | 97% | 17.08 | 419 / 430 |
esophagus | 91% | 1365.48 | 1318 / 1445 | 100% | 29.28 | 183 / 183 |
stomach | 90% | 1276.38 | 324 / 359 | 100% | 21.12 | 285 / 286 |
skin | 100% | 3127.93 | 1809 / 1809 | 89% | 14.29 | 421 / 472 |
breast | 91% | 873.13 | 416 / 459 | 89% | 9.08 | 994 / 1118 |
bladder | 76% | 980.86 | 16 / 21 | 98% | 15.94 | 493 / 504 |
intestine | 69% | 1179.23 | 665 / 966 | 99% | 19.89 | 521 / 527 |
brain | 67% | 663.19 | 1781 / 2642 | 96% | 14.27 | 677 / 705 |
pancreas | 66% | 405.82 | 217 / 328 | 96% | 21.83 | 170 / 178 |
uterus | 64% | 470.15 | 109 / 170 | 97% | 18.45 | 447 / 459 |
adrenal gland | 50% | 264.24 | 128 / 258 | 70% | 7.43 | 161 / 230 |
prostate | 84% | 963.64 | 206 / 245 | 16% | 0.76 | 82 / 502 |
lymph node | 0% | 0 | 0 / 0 | 100% | 20.72 | 29 / 29 |
spleen | 100% | 3056.51 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 18.13 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.02 | 1 / 1 |
adipose | 95% | 859.58 | 1149 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 71% | 1596.24 | 656 / 929 | 0% | 0 | 0 / 0 |
heart | 69% | 508.04 | 594 / 861 | 0% | 0 | 0 / 0 |
muscle | 60% | 597.10 | 478 / 803 | 0% | 0 | 0 / 0 |
liver | 11% | 62.23 | 25 / 226 | 44% | 3.65 | 178 / 406 |
blood vessel | 47% | 365.38 | 628 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 14% | 0.82 | 11 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006699 | Biological process | bile acid biosynthetic process |
GO_0006869 | Biological process | lipid transport |
GO_0032433 | Cellular component | filopodium tip |
GO_0005829 | Cellular component | cytosol |
GO_0097038 | Cellular component | perinuclear endoplasmic reticulum |
GO_0031965 | Cellular component | nuclear membrane |
GO_0005886 | Cellular component | plasma membrane |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0015485 | Molecular function | cholesterol binding |
Gene name | OSBPL3 |
Protein name | Oxysterol binding protein like 3 Oxysterol-binding protein-related protein 3 (ORP-3) (OSBP-related protein 3) |
Synonyms | ORP3 OSBP3 KIAA0704 |
Description | FUNCTION: Phosphoinositide-binding protein which associates with both cell and endoplasmic reticulum (ER) membranes . Can bind to the ER membrane protein VAPA and recruit VAPA to plasma membrane sites, thus linking these intracellular compartments . The ORP3-VAPA complex stimulates RRAS signaling which in turn attenuates integrin beta-1 (ITGB1) activation at the cell surface . With VAPA, may regulate ER morphology . Has a role in regulation of the actin cytoskeleton, cell polarity and cell adhesion . Binds to phosphoinositides with preference for PI(3,4)P2 and PI(3,4,5)P3 . Also binds 25-hydroxycholesterol and cholesterol . . |
Accessions | C9JZ19 ENST00000409069.5 [Q9H4L5-4] ENST00000409555.5 [Q9H4L5-8] ENST00000415162.5 Q9H4L5 ENST00000415952.1 ENST00000396429.5 [Q9H4L5-3] C9J8P4 ENST00000441059.5 ENST00000313367.7 [Q9H4L5-1] ENST00000409452.5 [Q9H4L5-5] ENST00000409863.5 [Q9H4L5-6] ENST00000409759.5 [Q9H4L5-7] C9JEF2 ENST00000396431.5 [Q9H4L5-2] |